ArticleUrology case reports2026
Neuroendocrine transformation of prostate adenocarcinoma with liver and brain metastases: case report and literature review.
Article in Urology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment-emergent neuroendocrine prostate cancer (t-NEPC) is a rare and aggressive variant associated with resistance to androgen deprivation therapy and visceral metastases. We report a case of neuroendocrine transformation of metastatic prostate adenocarcinoma with liver and brain involvement. Diagnosis was confirmed by liver biopsy demonstrating neuroendocrine differentiation and a Ki-67 index of 95%. A literature review identified seven similar cases. Platinum-based chemotherapy was the main treatment, with limited survival. Neuroendocrine transformation should be suspected in patients with rapid visceral progression despite low PSA levels. Metastatic-site biopsy remains essential for accurate diagnosis and treatment selection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.